Chinese precision oncology diagnostics company developing cancer molecular diagnostic services and related reagents
Chinese precision oncology diagnostics company developing cancer molecular diagnostic services and related reagents. Its offerings include next-generation sequencing (NGS) panels, liquid biopsy and ctDNA methylation testing, minimal residual disease (MRD) monitoring, early cancer screening, and companion diagnostics. The company reports proprietary AllNGS hybrid-capture technology and products for detecting mutations, insertions/deletions, fusions, and copy-number variations.